← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #865 OF 1,000 MOST-CITED

Manufacturing operations - prevent contamination

FDA cited this observation 17 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods17
BY FISCAL YEAR
FY20242
FY20232
FY20223
FY20211
FY20201
FY20193
FY20183
FY20172

How FDA worded it — real examples

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of components and dietary supplements.

Ultra Botanica, LLC · Oklahoma City, Oklahoma · Foods · 2024-01-19

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of dietary supplements.

Milk Specialties Company · Wautoma, Wisconsin · Foods · 2023-11-07

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of dietary supplements.

Universal Protein Supplements Corporation · New Brunswick, New Jersey · Foods · 2023-05-01

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of dietary supplements.

Eden's Answers Inc · Holmesville, Ohio · Foods · 2022-11-16

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of dietary supplements.

Country Life, LLC · Hauppauge, New York · Foods · 2022-05-13

You did not take necessary precautions during the manufacture of a dietary supplement to prevent contamination of dietary supplements.

Nutra Valley LLC · Nashport, Ohio · Foods · 2022-01-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Contamination controlFood industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →